Blog

Eugen Leo: Advancing Cancer Care – Tackling Cachexia and Tumor Resistance

Eugen Leo/catalym.com

Dec 13, 2024, 14:22

Eugen Leo: Advancing Cancer Care – Tackling Cachexia and Tumor Resistance

Eugen Leo, Chief Medical Officer at CatalYm GmbH and Founder and CEO of LEO Consulting, reshared a post on LinkedIn by CatalYm GmbH, adding:

“Blocking GDF15 has multiple benefits for cancer patients – and the world starts to realize this. Recently, the GDF-15 antibody ponsegromab demonstrated potent anti-cachexia effects in cachectic cancer patients [NEJM 2024].

For our GDF-15 antibody visugromab we observed a similar anti-cachexia effect in the subpopulation of our GDFATHER-01 first-in-human trial that suffered from similar cachectic conditions at baseline.

And all this on top of the remarkable antitumoral effects seen in combination with nivolumab in last-line, anti-PD1/PD-L1 relapsed/refractory patients, achieving deep, long-lasting remissions that in the majority of responding patients reached a depth as per RECIST 1.1 that had not been achieved with the initial anti-PD1/PD-L1 treatment regimen.

How is that possible? By GDF-15 blockade with visugromab.

See here a small educational video on what we observed regarding cachexia in our GDFATHER-01 trial and what visugromab can deliver on top as true I/O therapy for cancer patients in need.

And the best of all – More Good News to come soon. Stay tuned.”

Quoting CatalYm GmbH’s post:

“Advancing Cancer Care: Tackling Cachexia and Tumor Resistance.

At CatalYm, we are driven by a commitment to transform the lives of cancer patients through innovative approaches targeting GDF-15, a key regulator of both cancer therapy resistance and cachexia.

EuIn this video, Eugen Leo, our Chief Medical Officer, explains how neutralizing GDF-15 enhances the immune system’s ability to fight tumors by overcoming resistance to checkpoint inhibitors.

He also highlights the potential of this approach to reinvigorate and deepen responses in patients with advanced cancer, even in those who are refractory to standard treatments.

Additionally, he provides insights into GDF-15’s role in driving cachexia — a debilitating condition characterized by severe weight loss, muscle wasting, and reduced quality of life — showcasing the potential dual benefit of targeting this pathway.

Discover more about our innovative work and clinical programs at www.catalym.com.

Video attached to the post.

Eugen Leo